



Marc Julien

Co-CEO Diabeloop SA

Main product: D4Kids

Aim: To develop an automated type 1 diabetes management solution specifically designed for children



diabeloop.com

@Diabeloop

Diabeloop

diabeloop

Artificial intelligence to improve type 1 diabetes management for children

The project

The idea

We have developed an automated type 1 diabetes management system specifically for children, taking into account their particular physiology and the fact that they rely completely on adult caregivers. Our personalised solution acts as a sort of artificial pancreas, enabling the whole family to live their lives to the fullest while keeping the disease under control.

Partners are essential as nobody has the skills to face all the challenges of building innovative products and entering the market on their own.

Inspiration

People with type 1 diabetes have to take dozens of therapeutic decisions every day and night to avoid major health issues. We want to help them achieve better glycaemic control and relieve them as much as possible of the burden of the disease.

Unique selling points

D4Kids will be unique and the most effective closed-loop system automating glycemia management approved for children.

Societal impact

The impact is threefold: first, our solution helps patients better manage their disease and life. Second, healthcare costs related to the hospitalisation of children with type 1 diabetes will decrease. Finally, we create highly qualified jobs in the process.

EIT Community support

The EIT Community has helped us foster cross-border cooperation and facilitated the open innovation process in a major way.

Supported by:



Generated funding:
EUR 16 000 000

Challenge:
Automated diabetes management for kids

Partners:
CERITD, CEA-LETI, Profil Institut, KU Leuven

The nominee

The beginning

I have always been interested in medicine and I want to further human progress with the power of modern business. Joining Diabeloop was an opportunity that made perfect sense.

Partnerships & Teamwork

Diabeloop is the project leader and responsible for the development of the algorithms and regulatory questions with the help of the technology research institute CEA-LETI. The research center for diabetes treatment CERITD coordinated the clinical trials carried out by the Belgian university, KU Leuven. Profil defined the market access strategy.

Rewarding moments

During the Focus Groups with children, we were amazed by their spontaneity, creativity, and enthusiasm. The first clinical results and feedback of the children and parents are extremely promising.

